The higher sensitivity and specificity of the tumor-informed approach and in turn higher prognostic accuracy are likely driven by the ability to track a larger number of specific cancer-derived variants in the plasma and better ability to exclude variants related to CHIP (55). This evidence concerns the gene STUB1 and neoplasm.